Who is sponsoring NCT00104065?

NCT00104065 is sponsored by CuraGen Corporation.

What condition does NCT00104065 study?

NCT00104065 studies Stomatitis.

What drugs are being tested in NCT00104065?

Interventions: CG53135-05, velafermin.

What is the status of NCT00104065?

NCT00104065 is currently COMPLETED.

Last reviewed 2016-03-14 · How we verify

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant

NCT00104065 Phase 2 COMPLETED

CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objective of this Phase II trial is to evaluate the safety and efficacy of CG53135-05 when administered as a single dose to patients at risk for developing oral mucositis.

Details

Lead sponsor	CuraGen Corporation
Phase	Phase 2
Status	COMPLETED
Start date	2005-01
Completion	2005-12

Conditions

Stomatitis

Interventions

CG53135-05, velafermin

Countries

United States